ADCYAP1 and Parkinson disease: Administration of exogenous PACAP improved the outcomes in a variety of animal models, including traumatic brain injury[80], stroke [81], retinal ischemia [82], spinal cord injury [83], Parkinson’s disease [84], Huntington’s disease [85], and spinobulbar muscular atrophy [86].